anonymous
Guest
anonymous
Guest
Biogen's Aduhelm can't catch a break even in Alzheimer's trials as neurologists worry about safety, efficacy
https://www.fiercepharma.com/market...als-cms-decision-has-not-killed-hope-all-anti
https://www.fiercepharma.com/market...als-cms-decision-has-not-killed-hope-all-anti